Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Graft Versus Host Disease (GvHD) Treatment Market Outlook (2023 to 2033)

The global graft versus host disease (GvHD) treatment market size is expected to secure US$ 5,960.7 million by 2033 while expanding at a CAGR of 8.2%.

The GvHD treatment market is experiencing a steady growth in corticosteroids and combination therapies for graft-versus-host disease in HCT patients boosting the market for (GvHD) treatment. The market is likely to hold a value of US$ 2,713.6 million in 2023. From 2018 to 2022, the market displayed a growth rate of 8.2%.

Allogeneic hematopoietic cell transplant patients may benefit from recent advancements in overall survival rate and acute graft-versus-host disease (GVHD) severity levels, however, several challenges must be addressed. In addition, newer medications such as Jakafi and Rezurock have recently been approved for the prevention and treatment of chronic (GVHD) and may provide a greater benefit than older medications.

Data Points Key Statistics
Graft Versus Host Disease (GvHD) Treatment Market Value (2023) US$ 2,713.6 million
Graft Versus Host Disease (GvHD) Treatment Market Forecast Value (2033) US$ 5,960.7 million
Estimated Growth Rate (2023 to 2033) 8.2% CAGR

For treating adults and pediatric patients with GVHD, Orencia (abatacept) was approved by the United States Food and Drug Administration in December 2021. In addition to treating autoimmune disorders, Orencia is also used to prevent them. T-cells are a key component of acute (GVHD), and this drug circumvents their attack by specifically binding to and modulating one of the main costimulation signals sent by these cells.

This prevents a full activation of T-cells, which prevents acute (GVHD) from occurring. Several new approaches are being evaluated by doctors to prevent (GVHD) in the future.

Approval of Orencia is expected to make stem cell transplants more accessible to a larger number of cancer patients and people with blood disorders, particularly people from diverse ethnic backgrounds. To improve treatment response, future treatments may include immunosuppression and other treatment agents, such as regenerative or tissue-repairing agents to the market.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Factors Contributing to the Market Growth

A healthy CAGR is expected to be observed for graft versus host disease treatment during the forecast period. As innovative technologies are developed, and cancer patients seek out chemotherapy treatments, the graft versus host disease (GvHD) treatment market is expected to expand from 2023 to 2033.

Cancer patients who are treated with chemotherapy are the main driving force behind the graft versus host disease (GvHD) market at present. Increasing bone marrow transplants to treat specific cancers is also fueling the global graft versus host disease market.

Human health products have become increasingly innovative and effective in recent decades. Growth in graft versus host disease (GvHD) is projected to be considerably impacted by the use of allogeneic stem cell transplants.

To stay competitive, key players focus on introducing new drugs to the market. As a result of the high investments made by the public and private sectors in research and development technology and infrastructure, it is expected that the market is expected to be provided with lucrative opportunities shortly.

A global economy that focuses on advancing technology and innovation has the potential to restore growth and ensure the future competitiveness of the pharmaceutical industry by investing in innovation and research.

Trend The surging rate of acute GvHD, increasing rate of hematopoietic stem cell treatment, and rising number of pipeline drugs are catalyzing the demand for graft versus host disease (GvHD) treatment.
Supporting News
  • In October 2021, StatPearls Publishing published a report that found the incidence of acute GvHD was around 50% for patients getting HCT from matched siblings, Human Leukocyte Antigen (HLA), and unmatched donors.
  • In June 2021, Elsevier published an article that calculates 42% of American patients are suffering from cGvHD within three years of allogeneic HCT.
Trend Governments and industry players are heavily investing in research and development. The positive outcomes of these clinical trials are expected to result in new treatments, which are projected to propel industry growth.
Supporting News In June 2021, Equillium Inc. stated the completion of an End-of-Phase 1 meeting with the United States FDA for itolizumab in the treatment of aGvHD patients.
Trend Research studies to elevate the effectiveness of corticosteroids in the treatment
Supporting News In June 2022, a clinical trial was underway. It is a multicenter, open-label, two-arm randomized trial that assesses if the addition of ruxolitinib clubbed with corticosteroids is greater than corticosteroids to treat newly diagnosed aGvHD. A 50% response rate was reported for first-line therapy.

Factors Impeding the Adoption of Graft Versus Host Disease (GvHD) Treatments

Global graft versus host disease (GvHD) market growth is likely to be hindered by costs associated with recent clinical trials and authorizations. Using steroids in the treatment of (GvHD) immune diseases, skin diseases, and other conditions may result in side effects such as glucose levels increasing, fluid retention, mood problems, appetite disorders, and stomach pain.

The use of steroids over a long period has been linked to diabetes, infection, muscle weakness, and even cancer.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Regional Analysis

Region and their Market Share % (2022) Countries and their Share (2022)/ Forecast CAGR %
North America had a 34.7% Share The United States had a 30.7% Market Share
Europe had a 26.7% Share
  • Germany had a 3.8% Market Share
  • The United Kingdom to register 7.3% CAGR

North America to be Driven by the Approval of Regulatory Authority for Several Medicines

As per the research, the global graft versus host disease (GvHD) treatment market is expected to be dominated by North America during the forecast period. In 2023, the region is expected to secure more than 34.7% of the total market share. As a result of a well-established medical infrastructure and the proliferation of major key players in the region, the region has become a dominant market for (GvHD) treatments.

The United States is expected to contribute the most to the development of the market during the forecast period. Growing awareness of (GVHD) has boosted the market for (GvHD) treatments in this region. New medicines are expected to propel the market growth during the forecast period. Additionally, the regulatory authority's approval for various medicines in the market also contributes to the growth of the region.

For instance, on September 22, 2021, the FDA approved Ruxolitinib for chronic graft-versus-host disease ((GVHD)) in adults and children over 12 years of age who have failed one or more lines of systemic therapy. REACH-3 (NCT03112603) evaluated Ruxolitinib's efficacy as a treatment for corticosteroid-refractory chronic (GVHD) after allogeneic stem cell transplantation compared with the best available therapy (BAT) on the market.

Use of Advanced Cancer Treatment Technologies to Fuel Europe Market

According to the analysis, the Europe GvHD treatment market is projected to be a prominent market during the forecast period. It is estimated that the region is going to hold more than 26.5% of the total market share in 2023. The growth of the market can be attributed to the rapid development of the food and beverage sector in the region.

Growing awareness, the availability of chemotherapies, and the adoption of advanced cancer treatment technologies drive the market for graft versus host disease (GvHD) treatment in these regions. In addition, the rise in the aging population, scientific advancements, and clinical trials are expected to grow the market for GvHD treatment in the market.

Category-wise Insights

Monoclonal Antibodies to Emerge as the Effective Products for Treating GvHD

According to Future Market Insights, monoclonal antibodies are expected to gain significant market share in the upcoming years. With the rapid development of pharmaceuticals and clinical trials, along with the expanding treatment for chronic diseases, the worldwide market is set for continued expansion shortly.

The increasing number of cancer cases in various regions has fuelled the growth of this GvHD treatment market in recent years. Due to their specialization in targeted cancer therapies in the medical sector, monoclonal antibodies are in high demand due to their unique properties.

Some monoclonal antibodies are also immunotherapies since they are effective in fighting cancer by turning the immune system against the disease. These treatment types are therefore growing in the market.

Acute Graft Versus Host Disease (GvHD) to Infiltrate the Global Market

The use of various treatments for GvHD is expected to drive the market and account for the greatest share in 2023. Globally, the market is expected to expand at a significant CAGR, attracting private and public investments to this market.

Ruxolitinib is becoming more widely used as an alternative treatment option for acute graft versus host disease (GvHD), which reduces the need for hospitalization unless there are complications. Increasing immunosuppression is often successfully achieved through the administration of oral or intravenous steroid medications.

The severe complications of acute graft-versus-host disease (GVHD) continue to hinder the success of allogeneic hematopoietic stem cell transplants (HSCTs). As a treatment when prophylaxis fails or remains suboptimal, the ability to prevent (GVHD) prophylaxis is crucial. The most commonly prescribed regimen for prophylaxis of (GVHD) still consists of a calcineurin inhibitor in combination with methotrexate.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Start-up Companies Playing a Crucial Role in Augmenting Sales of Graft Versus Host Disease (GvHD) Treatment

Healthcare continues to be a flourishing sector, and the demand for safe and effective graft-versus-host-disease medications is on the rise. Numerous innovative medicine solutions have been introduced in the medical field to reduce side effects and improve long-term outcomes, including the incorporation of graft versus host disease (GvHD) treatment. As start-ups realize their potential, they are firmly establishing themselves on the global market.

Some notable graft versus host disease start-up manufacturers are as follows:

  • Astellas Pharma was founded in 2005 as a Japanese multinational pharmaceutical company formed from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. Several drugs have been developed by the company that are used effectively to treat (GVHD) diseases and other chronic diseases.
  • Mesoblast Ltd, the United Kingdom-based graft versus host disease (GvHD) treatment manufacturer, offers allogeneic cellular medicines that are being developed and commercialized by Mesoblast using its proprietary technology platform to treat diseases that are resistant to conventional treatments and in which inflammation is a significant factor. Among the Company's Phases, 3 products are remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-a(GVHD)), and for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection; REVASCOR® for severe chronic heart failure; and MPC-06-ID for degenerative disc disease-related chronic low back pain.
  • Equillium, Inc. develops unmet medical needs in the treatment of severe autoimmune and inflammatory disorders by leveraging a deep understanding of immunobiology. The company is situated in California, United States, and was founded in 2017. A Phase 3 study is currently underway for graft-versus-host disease patients and a Phase 1b trial has been initiated for patients with lupus/lupus nephritis patients. An alopecia areata study is expected to begin enrolling patients in the second half of 2022 with EQ101, a first-in-class tri-specific cytokine inhibitor that targets IL-2, IL-9, and IL-15.

Key Segments Profiled in Market

By Product:

  • Monoclonal antibodies
  • mTOR inhibitors
  • Tyrosine kinase inhibitors
  • Thalidomide
  • Etanercept

By Disease:

  • Acute Graft Versus Host Disease (aGvHD)
  • Chronic Graft Versus Host Disease (cGvHD)

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Frequently Asked Questions

What is the Graft Versus Host Disease Treatment Market Size in 2023?

The market is valued at US$ 2.7 billion in 2023.

Which are the key Market players?

Astellas Pharma, Mesoblast Ltd, and Equillium, Inc. are key market players.

What will the market size be in 2033?

The market will reach US$ 5.9 billion by 2033.

What drives the sales of Graft Versus Host Disease Treatment Market?

Increasing cases of acute GvHDwill drive the market prospects.

Which is the key segment by product?

Monoclonal antibodies segment is likely to remain preferred through 2033.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Product, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product, 2023 to 2033

        5.3.1. Monoclonal antibodies Graft Versus Host Disease (GvHD) Treatment

        5.3.2. mTOR inhibitors Graft Versus Host Disease (GvHD) Treatment

        5.3.3. Tyrosine kinase inhibitors Graft Versus Host Disease (GvHD) Treatment

        5.3.4. Thalidomide Graft Versus Host Disease (GvHD) Treatment

        5.3.5. Etanercept Graft Versus Host Disease (GvHD) Treatment

    5.4. Y-o-Y Growth Trend Analysis By Product, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Product, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Disease, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease, 2023 to 2033

        6.3.1. Acute Graft Versus Host Disease (a(GvHD))

        6.3.2. Chronic Graft Versus Host Disease (c(GvHD))

    6.4. Y-o-Y Growth Trend Analysis By Disease, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Disease, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Western Europe

        7.3.4. Eastern Europe

        7.3.5. South Asia and Pacific

        7.3.6. East Asia

        7.3.7. Middle East and Africa

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. USA

            8.2.1.2. Canada

        8.2.2. By Product

        8.2.3. By Disease

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Product

        8.3.3. By Disease

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Product

        9.2.3. By Disease

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Product

        9.3.3. By Disease

    9.4. Key Takeaways

10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. UK

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Western Europe

        10.2.2. By Product

        10.2.3. By Disease

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Product

        10.3.3. By Disease

    10.4. Key Takeaways

11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Poland

            11.2.1.2. Russia

            11.2.1.3. Czech Republic

            11.2.1.4. Romania

            11.2.1.5. Rest of Eastern Europe

        11.2.2. By Product

        11.2.3. By Disease

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Product

        11.3.3. By Disease

    11.4. Key Takeaways

12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Bangladesh

            12.2.1.3. Australia

            12.2.1.4. New Zealand

            12.2.1.5. Rest of South Asia and Pacific

        12.2.2. By Product

        12.2.3. By Disease

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Product

        12.3.3. By Disease

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Product

        13.2.3. By Disease

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Product

        13.3.3. By Disease

    13.4. Key Takeaways

14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Product

        14.2.3. By Disease

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Product

        14.3.3. By Disease

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. USA

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Product

            15.1.2.2. By Disease

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Product

            15.2.2.2. By Disease

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Product

            15.3.2.2. By Disease

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Product

            15.4.2.2. By Disease

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Product

            15.5.2.2. By Disease

    15.6. UK

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Product

            15.6.2.2. By Disease

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Product

            15.7.2.2. By Disease

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Product

            15.8.2.2. By Disease

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Product

            15.9.2.2. By Disease

    15.10. Poland

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Product

            15.10.2.2. By Disease

    15.11. Russia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Product

            15.11.2.2. By Disease

    15.12. Czech Republic

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Product

            15.12.2.2. By Disease

    15.13. Romania

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Product

            15.13.2.2. By Disease

    15.14. India

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Product

            15.14.2.2. By Disease

    15.15. Bangladesh

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Product

            15.15.2.2. By Disease

    15.16. Australia

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Product

            15.16.2.2. By Disease

    15.17. New Zealand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Product

            15.17.2.2. By Disease

    15.18. China

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Product

            15.18.2.2. By Disease

    15.19. Japan

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Product

            15.19.2.2. By Disease

    15.20. South Korea

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Product

            15.20.2.2. By Disease

    15.21. GCC Countries

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Product

            15.21.2.2. By Disease

    15.22. South Africa

        15.22.1. Pricing Analysis

        15.22.2. Market Share Analysis, 2022

            15.22.2.1. By Product

            15.22.2.2. By Disease

    15.23. Israel

        15.23.1. Pricing Analysis

        15.23.2. Market Share Analysis, 2022

            15.23.2.1. By Product

            15.23.2.2. By Disease

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Product

        16.3.3. By Disease

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Sanofi

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Equillium, Inc.

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. Novartis AG

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Neovii Biotech GmbH

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Merck & Co.

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Astellas Pharma Inc.

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Soligenix, Inc.

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Mesoblast Ltd

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Pfizer

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Takeda Pharmaceutical

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

        17.1.11. Abbott

            17.1.11.1. Overview

            17.1.11.2. Product Portfolio

            17.1.11.3. Profitability by Market Segments

            17.1.11.4. Sales Footprint

            17.1.11.5. Strategy Overview

                17.1.11.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Product, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Disease, 2018 to 2033

Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Product, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Disease, 2018 to 2033

Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 8: Latin America Market Value (US$ Million) Forecast by Product, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Disease, 2018 to 2033

Table 10: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 11: Western Europe Market Value (US$ Million) Forecast by Product, 2018 to 2033

Table 12: Western Europe Market Value (US$ Million) Forecast by Disease, 2018 to 2033

Table 13: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Eastern Europe Market Value (US$ Million) Forecast by Product, 2018 to 2033

Table 15: Eastern Europe Market Value (US$ Million) Forecast by Disease, 2018 to 2033

Table 16: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 17: South Asia and Pacific Market Value (US$ Million) Forecast by Product, 2018 to 2033

Table 18: South Asia and Pacific Market Value (US$ Million) Forecast by Disease, 2018 to 2033

Table 19: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 20: East Asia Market Value (US$ Million) Forecast by Product, 2018 to 2033

Table 21: East Asia Market Value (US$ Million) Forecast by Disease, 2018 to 2033

Table 22: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 23: Middle East and Africa Market Value (US$ Million) Forecast by Product, 2018 to 2033

Table 24: Middle East and Africa Market Value (US$ Million) Forecast by Disease, 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Product, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Disease, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 7: Global Market Value (US$ Million) Analysis by Product, 2018 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Product, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033

Figure 10: Global Market Value (US$ Million) Analysis by Disease, 2018 to 2033

Figure 11: Global Market Value Share (%) and BPS Analysis by Disease, 2023 to 2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by Disease, 2023 to 2033

Figure 13: Global Market Attractiveness by Product, 2023 to 2033

Figure 14: Global Market Attractiveness by Disease, 2023 to 2033

Figure 15: Global Market Attractiveness by Region, 2023 to 2033

Figure 16: North America Market Value (US$ Million) by Product, 2023 to 2033

Figure 17: North America Market Value (US$ Million) by Disease, 2023 to 2033

Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 22: North America Market Value (US$ Million) Analysis by Product, 2018 to 2033

Figure 23: North America Market Value Share (%) and BPS Analysis by Product, 2023 to 2033

Figure 24: North America Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Disease, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Disease, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Disease, 2023 to 2033

Figure 28: North America Market Attractiveness by Product, 2023 to 2033

Figure 29: North America Market Attractiveness by Disease, 2023 to 2033

Figure 30: North America Market Attractiveness by Country, 2023 to 2033

Figure 31: Latin America Market Value (US$ Million) by Product, 2023 to 2033

Figure 32: Latin America Market Value (US$ Million) by Disease, 2023 to 2033

Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 37: Latin America Market Value (US$ Million) Analysis by Product, 2018 to 2033

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Product, 2023 to 2033

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033

Figure 40: Latin America Market Value (US$ Million) Analysis by Disease, 2018 to 2033

Figure 41: Latin America Market Value Share (%) and BPS Analysis by Disease, 2023 to 2033

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Disease, 2023 to 2033

Figure 43: Latin America Market Attractiveness by Product, 2023 to 2033

Figure 44: Latin America Market Attractiveness by Disease, 2023 to 2033

Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 46: Western Europe Market Value (US$ Million) by Product, 2023 to 2033

Figure 47: Western Europe Market Value (US$ Million) by Disease, 2023 to 2033

Figure 48: Western Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 49: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 50: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 51: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 52: Western Europe Market Value (US$ Million) Analysis by Product, 2018 to 2033

Figure 53: Western Europe Market Value Share (%) and BPS Analysis by Product, 2023 to 2033

Figure 54: Western Europe Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033

Figure 55: Western Europe Market Value (US$ Million) Analysis by Disease, 2018 to 2033

Figure 56: Western Europe Market Value Share (%) and BPS Analysis by Disease, 2023 to 2033

Figure 57: Western Europe Market Y-o-Y Growth (%) Projections by Disease, 2023 to 2033

Figure 58: Western Europe Market Attractiveness by Product, 2023 to 2033

Figure 59: Western Europe Market Attractiveness by Disease, 2023 to 2033

Figure 60: Western Europe Market Attractiveness by Country, 2023 to 2033

Figure 61: Eastern Europe Market Value (US$ Million) by Product, 2023 to 2033

Figure 62: Eastern Europe Market Value (US$ Million) by Disease, 2023 to 2033

Figure 63: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 64: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 65: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 66: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 67: Eastern Europe Market Value (US$ Million) Analysis by Product, 2018 to 2033

Figure 68: Eastern Europe Market Value Share (%) and BPS Analysis by Product, 2023 to 2033

Figure 69: Eastern Europe Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033

Figure 70: Eastern Europe Market Value (US$ Million) Analysis by Disease, 2018 to 2033

Figure 71: Eastern Europe Market Value Share (%) and BPS Analysis by Disease, 2023 to 2033

Figure 72: Eastern Europe Market Y-o-Y Growth (%) Projections by Disease, 2023 to 2033

Figure 73: Eastern Europe Market Attractiveness by Product, 2023 to 2033

Figure 74: Eastern Europe Market Attractiveness by Disease, 2023 to 2033

Figure 75: Eastern Europe Market Attractiveness by Country, 2023 to 2033

Figure 76: South Asia and Pacific Market Value (US$ Million) by Product, 2023 to 2033

Figure 77: South Asia and Pacific Market Value (US$ Million) by Disease, 2023 to 2033

Figure 78: South Asia and Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 79: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 80: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 81: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 82: South Asia and Pacific Market Value (US$ Million) Analysis by Product, 2018 to 2033

Figure 83: South Asia and Pacific Market Value Share (%) and BPS Analysis by Product, 2023 to 2033

Figure 84: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033

Figure 85: South Asia and Pacific Market Value (US$ Million) Analysis by Disease, 2018 to 2033

Figure 86: South Asia and Pacific Market Value Share (%) and BPS Analysis by Disease, 2023 to 2033

Figure 87: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Disease, 2023 to 2033

Figure 88: South Asia and Pacific Market Attractiveness by Product, 2023 to 2033

Figure 89: South Asia and Pacific Market Attractiveness by Disease, 2023 to 2033

Figure 90: South Asia and Pacific Market Attractiveness by Country, 2023 to 2033

Figure 91: East Asia Market Value (US$ Million) by Product, 2023 to 2033

Figure 92: East Asia Market Value (US$ Million) by Disease, 2023 to 2033

Figure 93: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 94: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 95: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 97: East Asia Market Value (US$ Million) Analysis by Product, 2018 to 2033

Figure 98: East Asia Market Value Share (%) and BPS Analysis by Product, 2023 to 2033

Figure 99: East Asia Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033

Figure 100: East Asia Market Value (US$ Million) Analysis by Disease, 2018 to 2033

Figure 101: East Asia Market Value Share (%) and BPS Analysis by Disease, 2023 to 2033

Figure 102: East Asia Market Y-o-Y Growth (%) Projections by Disease, 2023 to 2033

Figure 103: East Asia Market Attractiveness by Product, 2023 to 2033

Figure 104: East Asia Market Attractiveness by Disease, 2023 to 2033

Figure 105: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 106: Middle East and Africa Market Value (US$ Million) by Product, 2023 to 2033

Figure 107: Middle East and Africa Market Value (US$ Million) by Disease, 2023 to 2033

Figure 108: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033

Figure 109: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 110: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 111: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 112: Middle East and Africa Market Value (US$ Million) Analysis by Product, 2018 to 2033

Figure 113: Middle East and Africa Market Value Share (%) and BPS Analysis by Product, 2023 to 2033

Figure 114: Middle East and Africa Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033

Figure 115: Middle East and Africa Market Value (US$ Million) Analysis by Disease, 2018 to 2033

Figure 116: Middle East and Africa Market Value Share (%) and BPS Analysis by Disease, 2023 to 2033

Figure 117: Middle East and Africa Market Y-o-Y Growth (%) Projections by Disease, 2023 to 2033

Figure 118: Middle East and Africa Market Attractiveness by Product, 2023 to 2033

Figure 119: Middle East and Africa Market Attractiveness by Disease, 2023 to 2033

Figure 120: Middle East and Africa Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Infectious Disease Diagnostics Market

Published : November 2022

Healthcare

Neurodegenerative Disease Market

Published : June 2022

Explore Healthcare Insights

View Reports

Graft Versus Host Disease (GvHD) Treatment Market